329 related articles for article (PubMed ID: 25892124)
1. Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors.
Lerman MA; Lewen MD; Kempen JH; Mills MD
Am J Ophthalmol; 2015 Jul; 160(1):193-200.e1. PubMed ID: 25892124
[TBL] [Abstract][Full Text] [Related]
2. Response of pediatric uveitis to tumor necrosis factor-α inhibitors.
Lerman MA; Burnham JM; Chang PY; Daniel E; Foster CS; Hennessy S; Jabs DA; Joffe MM; Kaçmaz RO; Levy-Clarke GA; Mills MD; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Kempen JH
J Rheumatol; 2013 Aug; 40(8):1394-403. PubMed ID: 23818712
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
[TBL] [Abstract][Full Text] [Related]
5. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
[TBL] [Abstract][Full Text] [Related]
6. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.
Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Januschowski K; Voykov B; Deuter C
Br J Ophthalmol; 2014 Apr; 98(4):523-8. PubMed ID: 24457365
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab in the therapy of uveitis in childhood.
Biester S; Deuter C; Michels H; Haefner R; Kuemmerle-Deschner J; Doycheva D; Zierhut M
Br J Ophthalmol; 2007 Mar; 91(3):319-24. PubMed ID: 17035274
[TBL] [Abstract][Full Text] [Related]
9. Infliximab for juvenile idiopathic arthritis-associated uveitis.
Richards JC; Tay-Kearney ML; Murray K; Manners P
Clin Exp Ophthalmol; 2005 Oct; 33(5):461-8. PubMed ID: 16181269
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.
Assa A; Hartman C; Weiss B; Broide E; Rosenbach Y; Zevit N; Bujanover Y; Shamir R
J Crohns Colitis; 2013 Jun; 7(5):369-76. PubMed ID: 22483567
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
12. Infliximab and adalimumab for uveitis.
Martel JN; Esterberg E; Nagpal A; Acharya NR
Ocul Immunol Inflamm; 2012 Feb; 20(1):18-26. PubMed ID: 22324897
[TBL] [Abstract][Full Text] [Related]
13. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab.
Simonini G; Taddio A; Cattalini M; Caputo R; De Libero C; Naviglio S; Bresci C; Lorusso M; Lepore L; Cimaz R
Arthritis Care Res (Hoboken); 2011 Apr; 63(4):612-8. PubMed ID: 21452272
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
Foeldvari I; Nielsen S; Kümmerle-Deschner J; Espada G; Horneff G; Bica B; Olivieri AN; Wierk A; Saurenmann RK
J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNFα Treatment for HLA-B27-Positive Ankylosing Spondylitis-Related Uveitis.
Kim M; Won JY; Choi SY; Ju JH; Park YH
Am J Ophthalmol; 2016 Oct; 170():32-40. PubMed ID: 27470062
[TBL] [Abstract][Full Text] [Related]
16. Recurrence of uveitis after discontinuation of infliximab.
Shakoor A; Esterberg E; Acharya NR
Ocul Immunol Inflamm; 2014 Apr; 22(2):96-101. PubMed ID: 23876234
[TBL] [Abstract][Full Text] [Related]
17. Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNFα therapy and discontinuation of glucocorticoids.
Brabnikova Maresova K; Jarosova K; Pavelka K; Stepan JJ
Rheumatol Int; 2013 Aug; 33(8):2001-7. PubMed ID: 23370856
[TBL] [Abstract][Full Text] [Related]
18. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
19. Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.
Pastore S; Naviglio S; Canuto A; Lepore L; Martelossi S; Ventura A; Taddio A
Paediatr Drugs; 2018 Apr; 20(2):165-171. PubMed ID: 29214394
[TBL] [Abstract][Full Text] [Related]
20. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
